Search

Background Objectives Methods Results Conclusion Neomycin is an aminoglycoside antibiotic that may cause contact allergy. It was withdrawn as a medicine for human use in Denmark in October 2009 but is still found in some vaccines.To identify time trends in contact allergy to neomycin in the period from 2000 to 2023.A cross‐section study of patients ≥18 years consecutively patch‐tested with neomycin sulfate (20% in pet.) at Gentofte Hospital, Denmark, during the period 2000–2023 was conducted.The overall prevalence of contact allergy to neomycin was 1.4%. The prevalence was significantly lower in the period ‘2010–2023’ (1.2%) than in ‘2000–2009’ (1.8%) (p < 0.005). Contact allergy to neomycin was significantly positively associated with facial dermatitis and age >40 years, and significantly negatively associated with occupational dermatitis and hand dermatitis. No changes in sex, occupational dermatitis, atopic dermatitis, hand dermatitis, leg dermatitis, facial dermatitis, or age > 40/≤40 (the MOAHLFA‐index) were identified when comparing neomycin contact allergic‐patients in the two periods ‘2010–2023’ and ‘2001–2009’.Neomycin is a rare cause of contact allergy in Denmark with a significantly lower prevalence following its withdrawal as a medicinal product for human use in Denmark in 2009. [ABSTRACT FROM AUTHOR]

This document is a summary of two scientific articles related to contact allergies. The first article focuses on the prevalence of contact allergy to N-isopropyl-N0-phenyl paraphenylenediamine (IPPD) in eczema patients in Denmark. The study found a low prevalence of IPPD contact allergy, with no significant associations between the allergy and various variables. The second article discusses the prevalence of occupational contact allergies in Europe based on patch test data collected from 2011 to 2020. The study provides insights into the types and frequency of allergens causing contact allergies. Both articles provide valuable information for researchers studying contact allergies. [Extracted from the article]